HHS Secretary Alex Azar told Senate Finance Committee members Thursday (March 14) that he still believes the Trump administration’s proposed rule to ban rebates in Medicare and Medicaid managed care would lower list prices and expand to the commercial market without legislation. Both drug makers lowering list prices and private plans and pharmacy benefit managers passing through rebates to enrollees would be voluntary actions unless Congress determines otherwise. Azar also said drug companies are gaming patents to delay biosimilar competition,...